GLOBAL BRONCHODILATORS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Bronchodilators Market, By Drug Class (Beta-adrenergic Bronchodilators, Xanthine Derivatives, Anticholinergic Bronchodilators), By Route of Administration (Oral, Nasal, Injectable), By Indication (Asthma, Chronic Obstructive Pulmonary Disease, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

Global Bronchodilators Market- Recent Developments

Product Approval/Launch

On July 21, 2023, Lupin, a global pharmaceutical company, announced that it had launched Luforbec100/6 (beclometasone 100µg/for moterol 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany
In September 2020, GSK plc., a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.

Distribution Agreement

In January 2022, Covis Pharma Canada Ltd., a subsidiary company of Covis Pharma, announced that it had entered into an exclusive promotion and distribution agreement with Novartis Pharmaceuticals Canada Inc., a subsidiary company of Novartis AG, whereby Covis has been appointed as Novartis’ exclusive partner to promote and distribute PrSeebri Breezhaler and PrUltibro Breezhaler in Canada

Global Bronchodilators Market Report Snapshots